GeNeuro Publishes its 2024 Universal Registration Document

GENEVA, Switzerland--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which has been filed on April 30, 2024 with the “Autorité des Marchés Financiers (AMF)”